Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Corticosteroid
|
| gptkbp:ATCCode |
D07AB01
|
| gptkbp:CASNumber |
987-24-6
|
| gptkbp:chemicalFormula |
C24H31FO6
|
| gptkbp:has_parent_compound |
gptkb:betamethasone
|
| https://www.w3.org/2000/01/rdf-schema#label |
betamethasone acetate
|
| gptkbp:is_a_prodrug_of |
gptkb:betamethasone
|
| gptkbp:IUPACName |
(11β,16β)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 21-acetate
|
| gptkbp:listedOn |
gptkb:World_Health_Organization's_List_of_Essential_Medicines
|
| gptkbp:marketedAs |
Celestone Acetate
|
| gptkbp:meltingPoint |
220-225°C
|
| gptkbp:molecularWeight |
434.5 g/mol
|
| gptkbp:routeOfAdministration |
topical
intramuscular intra-articular |
| gptkbp:sideEffect |
hyperglycemia
adrenal suppression skin thinning |
| gptkbp:usedFor |
immunosuppression
anti-inflammatory therapy |
| gptkbp:bfsParent |
gptkb:Osurnia
|
| gptkbp:bfsLayer |
7
|